AI drug development company Generate Biomedicines has raised USD 273 million in a Series C funding round led by Amgen, with participation from NVentures, MAPS Capital, Pictet Alternative Advisors, and other existing investors. This brings the total fund raised by the company to USD 693 million.
The funds will support the advancement of the company’s pipeline of protein therapies, enhance its generative biology platform, pursue collaborations, and invest in new program starts. The company plans to file a Clinical Trial Application for its anti-TSLP monoclonal antibody by early Q4 2023 and initiate multiple clinical trials annually. In addition, Generate Biomedicines also aims to submit multiple Investigational New Drug (IND) applications in 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.